Altimmune appointed Peter Greenleaf and Alex Howarth as new directors effective November 2, 2026, expanding the board from nine to eleven members. Greenleaf brings prior CEO experience at Aurinia Pharmaceuticals and MedImmune, while Howarth previously served as CFO of Madrigal Pharmaceuticals. Concurrently, John Gill, Mitchel Sayare, and Klaus Schafer announced their retirement from the board, with their terms concluding at the 2027 annual meeting. The appointments align with the company's transition to a late-stage clinical developer advancing pemvidutide for liver diseases. Altimmune is a biopharmaceutical company developing pemvidutide for serious liver diseases.
